Genes and Development Attend a BioResearch Product Faire

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

GENES & DEVELOPMENT 21:3214-3231, 2007
©2007 by Cold Spring Harbor Laboratory Press; ISSN 0890-9369/ $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharma, S. V.
Right arrow Articles by Settleman, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharma, S. V.
Right arrow Articles by Settleman, J.
Related Content
Right arrow Cancer and Disease Models
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

REVIEW

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

Sreenath V. Sharma and Jeffrey Settleman1

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA

In pugilistic parlance, the one-two punch is a devastating combination of blows, with the first punch setting the stage and the second delivering the knock-out. This analogy can be extended to molecularly targeted cancer therapies, with oncogene addiction serving to set the stage for tumor cell killing by a targeted therapeutic agent. While in vitro and in vivo examples abound documenting the existence of this phenomenon, the mechanistic underpinnings that govern oncogene addiction are just beginning to emerge. Our current inability to fully exploit this weakness of cancer cells stems from an incomplete understanding of oncogene addiction, which nonetheless represents one of the rare chinks in the formidable armor of cancer cells.

[Keywords: Oncogene addiction; cancer; targeted therapy; signal transduction]]

1 Corresponding author.

E-MAIL settleman{at}helix.mgh.harvard.edu; FAX (617) 726-7808.

Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.1609907


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Zhang, G. Ge, R. Meyer, S. Sethi, D. Basu, S. Pradhan, Y.-J. Zhao, X.-N. Li, W.-W. Cai, A. K. El-Naggar, et al.
Overexpression of Separase induces aneuploidy and mammary tumorigenesis
PNAS, September 2, 2008; 105(35): 13033 - 13038.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. A. Byron, M. G. Gartside, C. L. Wellens, M. A. Mallon, J. B. Keenan, M. A. Powell, P. J. Goodfellow, and P. M. Pollock
Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation
Cancer Res., September 1, 2008; 68(17): 6902 - 6907.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Montagut, S. V. Sharma, T. Shioda, U. McDermott, M. Ulman, L. E. Ulkus, D. Dias-Santagata, H. Stubbs, D. Y. Lee, A. Singh, et al.
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
Cancer Res., June 15, 2008; 68(12): 4853 - 4861.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Genome Res. Learn. Mem.
Protein Science RNA Genes Dev.
Copyright © 2007 by Cold Spring Harbor Laboratory Press.